Cystic fibrosis precision therapeutics: Emerging considerations. (12th November 2019)

• Record Type: Journal Article
• Authors: Joshi, Disha; Ehrhardt, Annette; Hong, Jeong S.; Sorscher, Eric J.
• Other Names: Murphy Thomas guestEditor.; Noah Terry guestEditor.
• Is Part Of: Pediatric pulmonology. Volume 54(2019)Supplement 3
• Page Start: S13
• Page End: S17
• Publication Date: 2019-11-12
• Subjects: combination drug therapy -- investigational drugs -- personalized medicine; Pediatric respiratory diseases -- Periodicals; Pediatrics -- Periodicals; 618.922
• DOI: 10.1002/ppul.24547
• Languages: English
• ISSNs: 8755-6863

Abstract

Abstract: Small molecules that address fundamental defects underlying cystic fibrosis (CF), including modulators such as the approved drugs ivacaftor, lumacaftor, tezacaftor, and elexacaftor, have advanced dramatically over the past few years and are transforming care and prognosis among individuals with this disease. The new treatment strategies are predicated on established scientific insight concerning pathogenesis, and applying "personalized" or "precision" interventions for specific abnormalities of the cystic fibrosis transmembrane conductance regulator (CFTR). Even with the advent of highly effective triple drug combinations—which hold great promise for the majority of patients with CF worldwide—barriers to precision therapy remain. These include refractory CFTR variants (premature truncation codons, splice defects, large indels, severe missense mutations, and others) not addressed by available modulators, and access to leading‐edge therapeutic compounds for patients with ultrarare forms of CF. In addition to describing the remarkable progress that has occurred regarding CF precision medicine, this review outlines some of the remaining challenges. The CF experience is emblematic of many conditions for which personalized interventions are actively being sought.